Myeloma is a blood cancer, which CAR-T has been wonderfully...

Myeloma is a blood cancer, which CAR-T has been wonderfully successful at treating, but that only represents ~10% of cancer types.

The exciting thing about our recent CF33-CD19 breakthrough is that using the CF33 as a delivery vessel we are now able to attack solid tumour (the remaining 90% of cancer type) both with the virus itself in addition to using the same type of treatment, CAR-T, that is proving so successful in blood cancers.

100% ORR (50% CR) as per the article in relapsed multiple myeloma. Now imagine a similar result in solid tumour and you can see why the IMU team and shareholders (when they aren't looking anxiously at the charts the past couple of days) are so excited.